CASP9 and breast cancer: Furthermore, miR-224 directly suppresses caspase-9 (CASP9) by targeting its mRNA, and knockdown of miR-224 in MDA-MB-231 cells significantly restores CASP9 protein levels, thereby inhibiting cell proliferation, migration, and invasion, suggesting preclinical drug candidate for breast cancer patients (Zhang et al., 2019).